Clinical implications of PTEN loss in prostate cancer (Q49818398)

22 February 2018

title

Clinical implications of PTEN loss in prostate cancer (English)

1 reference

22 February 2018

1 reference

Ashley E Ross

1 reference

22 February 2018

Tamara L Lotan

1 reference

22 February 2018

Angelo M De Marzo

1 reference

22 February 2018

Howard I. Scher

object named as

Howard I Scher

1 reference

22 February 2018

author name string

Tamara Jamaspishvili

1 reference

22 February 2018

David M Berman

1 reference

22 February 2018

Jeremy A Squire

1 reference

22 February 2018

language of work or name

English

0 references

publication date

20 February 2018

1 reference

22 February 2018

published in

Nature Reviews Urology

1 reference

22 February 2018

cites work

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The Molecular Taxonomy of Primary Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Integrative genomic profiling of human prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The functions and regulation of the PTEN tumour suppressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The tumor suppressor PTEN has a critical role in antiviral innate immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The functions of tumor suppressor PTEN in innate and adaptive immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Essential role for nuclear PTEN in maintaining chromosomal integrity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The genomic complexity of primary human prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Analysis of PTEN and the 10q23 region in primary prostate carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

ThePTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The mutational landscape of lethal castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Integrative clinical genomics of advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Evidence for molecular differences in prostate cancer between African American and Caucasian men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Mutational Landscape of Aggressive Prostate Tumors in African American Men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Considerations when analyzing the methylation status of PTEN tumor suppressor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

31 March 2020

Focus on PTEN Regulation

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Promoter methylation of the PTEN gene is a common molecular change in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Non-genomic loss of PTEN function in cancer: not in my genes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Tenets of PTEN tumor suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The evolutionary history of lethal metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Tracking the clonal origin of lethal prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Pten dose dictates cancer progression in the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Pten is essential for embryonic development and tumour suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Pten inactivation and the emergence of androgen-independent prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Mouse models of prostate cancer: picking the best model for the question.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Low-risk Prostate Cancer: Identification, Management, and Outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Active surveillance for prostate cancer: a narrative review of clinical guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Differential Diagnosis of Intraductal Lesions of the Prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Premalignancy in Prostate Cancer: Rethinking What we Know

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Therapeutic targeting of cancers with loss of PTEN function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

The PI3K Pathway in Human Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

DNA Repair in Prostate Cancer: Biology and Clinical Implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A secreted PTEN phosphatase that enters cells to alter signaling and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Relevance and therapeutic possibility of PTEN-long in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Immunotherapy for prostate cancer: an emerging treatment modality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Inflammation in prostate carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Immune Infiltration and Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

A PTENtial cause for the selectivity of oncolytic viruses?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

STAT3 regulated ARF expression suppresses prostate cancer metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

STATs in cancer inflammation and immunity: a leading role for STAT3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

7 January 2021

inferred from DOI database lookup

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

7 January 2021

inferred from DOI database lookup

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2018.9

7 January 2021

inferred from DOI database lookup

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer

1 reference

12 December 2020

Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues

1 reference

12 December 2020

Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas

1 reference

12 December 2020

High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice

1 reference

12 December 2020

A robust immunohistochemical assay for detecting PTEN expression in human tumors

1 reference

12 December 2020

PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis.

1 reference

12 December 2020

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System

1 reference

12 December 2020

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer

1 reference

12 December 2020

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2018.9

1 reference

22 February 2018

Dimensions Publication ID

1101125387

0 references

1 reference

22 February 2018